Home > Dermatology > AAD 2022 > Atopic Dermatitis: Novel Agents Enter the Stage > Novel IL-4/IL-13 blocker shows high efficacy with only modest conjunctivitis signal

Novel IL-4/IL-13 blocker shows high efficacy with only modest conjunctivitis signal

Presented By
Prof. Andrew Blauvelt, Oregon Medical Research Center, USA
Presented by
Andrew Blauvelt
Conference
AAD 2022
Eblasakimab, a new IL-4/IL-13 blocker, showed to be remarkably effective in a proof-of-concept study in patients with moderate-to-severe atopic dermatitis (AD). Moreover, only a few patients had conjunctivitis, which can be explained by the slightly different mode of action of the novel antibody. Both IL-4 and IL-13 are pivotal cytokines involved in the pathogenesis of AD and other allergic diseases. Despite effective approved treatment options for AD, some patients still have an inadequate response. Safety concerns, in particular conjunctivitis, also exist for these therapies. Eblasakimab is a first-in-class molecule with a novel mechanism of action. The drug selectively targets the IL-13 receptor (R) α1 and blocks both IL-4 and IL-13 signalling through the type 2 receptor. Selective targeting of the type 2 receptor (and sparing type 1 receptor signalling) offers the potential to avoid unwanted effects. “Dupilumab blocks all of IL-4 while this drug...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on